NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons
Ana Antonic, Mirella Dottori, Malcolm R Macleod, Geoffrey A Donnan, David W Howells
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES | ELSEVIER SCIENCE BV | Published : 2018
BACKGROUND: Developing new medicines is a complex process where understanding the reasons for both failure and success takes us forward. One gap in our understanding of most candidate stroke drugs before clinical trial is whether they have a protective effect on human tissues. NXY-059 is a spin-trap reagent hypothesized to have activity against the damaging oxidative biology which accompanies ischemic stroke. Re-examination of the preclinical in vivo dataset for this agent in the wake of the failed SAINT-II RCT highlighted the presence of a range of biases leading to overestimation of the magnitude of NXY-059's effects in laboratory animals. Therefore, NXY-059 seemed an ideal candidate to ev..View full abstract
The Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the NHMRC and the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.